Chris Leamon, PhD, Vice President of Research, Endocyte, notes Endocyte’s goals for developing targeted medicines using small molecule drug conjugate platforms. Vintafolide, Endocyte’s lead product, contains a drug called vinca alkaloid, which prevents cells from dividing. Dr. Leamon further explains the mechanisms that make vintafolide such a promising cancer therapy.

Press Releases:

Phase 2B Target Trial Results

European CHMP Positive Opinions